Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

Human Gene Therapy

Volumn 10, Issue 17, 1999, Pages 2741-2755

  Todo, Tomoki ^a   Rabkin, Samuel D ^a   Sundaresan, Periasamy ^a   Wu, Aiguo ^a   Meehan, Kenneth R ^a   Herscowitz, Herbert B ^a   Martuza, Robert L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; G 207; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN PROTECTION; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; MOUSE; NONHUMAN; REPLICON; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; FEMALE; GENETIC VECTORS; IMMUNOTHERAPY; MICE; NEUROBLASTOMA; SIMPLEXVIRUS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VIRUS REPLICATION;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0033589694     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950016483     Document Type: Article

References (65)

1. ALBERT, M.L., SAUTER, B., and BHARDWAJ, N. (1998). Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (London) 392, 86-89.
2. AMANO, T., RICHELSON, E., and NIRENBERG, M. (1972). Neurotransmitter synthesis by neuroblastoma clones. Proc. Natl. Acad. Sci. U.S.A. 69, 258-263.
3. ANDREANSKY, S., HE, B., VAN COTT, J., McGHEE, J., MARKERT, J.M., GILLESPIE, G.Y., ROIZMAN, B., and WHITLEY, R.J. (1998). Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5, 121-130.
4. BARBA, D., HARDIN, J., SADELAIN, M., and GAGE, F.H. (1994). Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. U.S.A. 91, 4348-4352.
5. BISCHOFF, J.R., KIRN, D.H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., NG, L., NYE, J.A., SAMPSON-JOHANNES, A., FATTAEY, A., and McCORMICK, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
6. BOONE, C.W., and BLACKMAN, K. (1972). Augmented immunogenicity of tumor cell homogenates infected with influenza virus. Cancer Res. 32, 1018-1022.
7. BOVIATSIS, E.J., SCHARF, J.M., CHASE, M., HARRINGTON, K., KOWALL, N.W., BREAKEFIELD, X.O., and CHIOCCA, E.A. (1994). Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors detective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1, 323-331.
8. BUCK, B.E., McALACK, R.F., SCHLESINGER, H., HICKS, N., and HUMMELER, K. (1977). Metastatic characteristics of murine neuroblastoma: A model for the human disease. Fed. Proc. 36, 1086.
9. CASTLEBERRY, R.P. (1997). Neuroblastoma. Eur. J. Cancer 33, 1430-1437.
10. CHAHLAVI, A., RABKIN, S.D., TODO, T., SUNDARESAN, P., and MARTUZA, R.L. (1999). Effect of prior exposure to herpes simplex virus 1 on viral vector mediated tumor therapy in immunocompetent mice. Gene Ther. 6, 1751-1758.
11. CHAMBERS, R., GILLESPIE, G.Y., SOROCEANU, L., ANDREANSKY, S., CHATTERJEE, S., CHOU, J., ROIZMAN, B., and WHITLEY, R.J. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma. Proc. Natl. Acad. Sci. U.S.A. 92, 1411-1415.
12. CHOU, J., KERN, E.R., WHITLEY, R.J., and ROIZMAN, B. (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science 250, 1262-1266.
13. COFFEY, M.C., STRONG, J.E., FORSYTH, P.A., and LEE, P.W.K. (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282, 1332-1334.
14. FODSTAD, Ø. (1991). Transplantability of human tumors. In The Nude Mouse in Oncology Research. E. Boven and B. Winograd, eds. (CRC Press, Boca Raton, FL) pp. 65-80.
15. GOLDSTEIN, D.J., and WELLER, S.K. (1988). Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62, 196-205.
16. GOPAS, J., ITZHAKY, D., SEGEV, Y., SALZBERG, S., TRINK, B., ISAKOV, N., and RAGER-ZISMAN, B. (1992). Persistent measles virus infection enhances major histocompatibility complex class I expression and immunogenicity of murine neuroblastoma cells. Cancer Immunol. Immunother. 34, 313-320.
17. GORDON, L.B., NOLAN, S.C., CSERR, H.F., KNOPF, P.M., and HARLING-BERG, C.J. (1997). Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination. J. Immunol. 159, 2399-2408.
18. HEICAPPELL, R., SCHIRRMACHER, V., VON HOEGEN, P., AHLERT, T., and APPELHANS, B. (1986). Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int. J. Cancer 37, 569-577.
19. HICKEY, W. (1991). Migration of hematogenous cells through the blood brain barrier and the initiation of CNS inflammation. Brain Pathol. 1, 97-105.
20. HUANG, A.Y., GOLUMBEK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D., and LEVITSKY, H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965.
21. JIA, W.W., McDERMOTT, M., GOLDIE, J., CYNADER, M., TAN, J., and TUFARO, F. (1994). Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J. Natl. Cancer Inst. 86, 1209-1215.
22. JUTILA, J.W., WEISNER, R.S., and EVANS, C.A. (1962). Immunization of the A/Jax mouse with irradiated cells of its indigenous tumour, sarcoma I. Nature (London) 195, 301.
23. KANANGAT, S., BABU, J.S., KNIPE, D.M., and ROUSE, B.T. (1996). HSV-1-mediated modulation of cytokine gene expression in a permissive cell line: Selective upregulation of IL-6 gene expression. Virology 219, 295-300.
24. KAPLITT, M.G., TJUVAJEV, J.G., LEIB, D.A., BERK, J., PETTIGREW, K.D., POSNER, J.B., PFAFF, D.W., RABKIN, S.D., and BLASBERG, R.G. (1994). Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J. Neurooncol. 19, 137-147.
25. KESARI, S., RANDAZZO, B.P., VALYI-NAGY, T., HUANG, Q.S., BROWN, S.M., MACLEAN, A.R., LEE, V.M., TROJANOWSKI, J.Q., and FRASER, N.W. (1995). Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest. 73, 636-648.
26. KESARI, S., LASNER, T.M., BALSARA, K.R., RANDAZZO, B.P., LEE, V.M., TROJANOWSKI, J.Q., and FRASER, N.W. (1998). A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. J. Gen. Virol. 79, 525-536.
27. KRAMM, C.M., RAINOV, N.G., SENA-ESTEVES, M., CHASE, M., PECHAN, P.A., CHIOCCA, E.A., and BREAKEFIELD, X.O. (1996). Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum. Gene Ther. 7, 291-300.
28. KRAMM, C.M., CHASE, M., HERRLINGER, U., JACOBS, A., PECHAN, P.A., RAINOV, N.G., SENA-ESTEVES, M., AGHI, M., CHIOCCA, E.A., and BREAKEFIELD, X.O. (1997). Therapeutic efficiency and safety of a second-generation replication-competent HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8, 2057-2068.
29. KURTZ, A., ZIMMER, A., SCHNUTGEN, F., BRUNING, G., SPENER, F., and MULLER, T. (1994). The expression pattern of a novel gene encoding brain-fatty acid binding protein correlates with neuronal and glial cell development. Development 120, 2637-2649.
30. LASNER, T.M., KESARI, S., BROWN, S.M., LEE, V.M., FRASER, N.W., and TROJANOWSKI, J.Q. (1996). Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J. Neuropathol. Exp. Neurol. 55, 1259-1269.
31. LASNER, T.M., TAL-SINGER, R., KESARI, S., LEE, V.M., TROJANOWSKI, J.Q., and FRASER, N.W. (1998). Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. J. Neurovirol. 4, 100-105.
32. LEE, S.S., EISENLOHR, L.C., McCUE, P.A., MASTRANGELO, M.J., and LATTIME, B.C. (1994). Intravesical gene therapy: In vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res. 54, 3325-3328.
33. LINDENMANN, J. (1974). Viruses as immunological adjuvants in cancer. Biochim. Biophys. Acta 355, 49-75.
34. LINDENMANN, J., and KLEIN, P.A. (1967). Viral oncolysis: Increased immunogenicity of host cell antigen associated with influenza virus. J. Exp. Med. 126, 93-108.
35. LOPEZ, C. (1975). Genetics of natural resistance to herpesvirus infections in mice. Nature (London) 258, 152-155.
36. LORENCE, R.M., REICHARD, K.W., KATUBIG, B.B., REYES, H.M., PHUANGSAB, A., MITCHELL, B.R., CASCINO, C.J., WALTER, R.J., and PEEPLES, M.E. (1994). Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J. Natl. Cancer Inst. 86, 1228-1233.
37. MARKERT, J.M., MALICK, A., COEN, D.M., and MARTUZA, R.L. (1993). Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 32, 597-603.
38. MARTUZA, R.L., MALICK, A., MARKERT, J.M., RUFFNER, K.L., and COEN, D.M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856.
39. McMENAMIN, M.M., BYRNES, A.P., CHARLTON, H.M., COFFIN, R.S., LATCHMAN, D.S., and WOOD, M.J. (1998). A gamma34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. Neuroscience 83, 1225-1237.
40. MINETA, T., RABKIN, S.D., and MARTUZA, R.L. (1994). Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54, 3963-3966.
41. MINETA, T., RABKIN, S.D., YAZAKI, T., HUNTER, W.D., and MARTUZA, R.L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1, 938-943.
42. MIYATAKE, S., IYER, A., MARTUZA, R.L., and RABKIN, S.D. (1997). Transcriptional targeting of herpes simplex virus for cell-specific replication. J. Virol. 71, 5124-5132.
43. PYLES, R.B., WARNICK, R.E., CHALK, C.L., SZANTI, B.E., and PARYSEK, L.M. (1997). A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8, 533-544.
44. RADHAKRISHNAN, K., BOHNEN, N.I., and KURLAND, L.T. (1994). Epidemiology of brain tumors. In Brain Tumors: A Comprehensive Text. R.A. Morantz and J.W. Walsh, eds. (Marcel Dekker, New York) pp. 1-18.
45. RAMAKRISHNAN, R., LEVINE, M., and FINK, D.J. (1994). PCR-based analysis of herpes simplex virus type 1 latency in the rat trigeminal ganglion established with a ribonucleotide reductase-deficient mutant. J. Virol. 68, 7083-7091.
46. RANDAZZO, B.P., KESARI, S., CESSER, R.M., ALSOP, D., FORD, J.C., BROWN, S.M., MACLEAN, A., and FRASER, N.W. (1995). Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211, 94-101.
47. RECOMBINANT DNA ADVISORY COMMITTEE (1998). Regulatory Issues: Summary of protocol discussed at the June 18-19, 1998 Recombinant DNA Advisory Committee (RAC) meeting: ORDA gene transfer protocol registration: 9802-235 (a dose escalating phase I study of the treatment of malignant glioma with G207, a genetically engineered HSV-1). Hum. Gene Ther. 9, 2154-2155.
48. RODRIGUEZ, R., SCHUUR, E.R., LIM, H.Y., HENDERSON, G.A., SIMONS, J.W., and HENDERSON, D.R. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559-2563.
49. SAVAGE, H.E., ROSSEN, R.D., HERSH, E.M., FREEDMAN, R.S., BOWEN, J.M., and PLAGER, C. (1986). Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells. Cancer Res. 46, 2127-2133.
50. SINKOVICS, J., and HORVATH, J. (1993). New developments in the virus therapy of cancer: A historical review. Intervirology 36, 193-214.
51. SONG, C.W., KANG, M.S., RHEE, J.G., and LEVITT, S.H. (1980). Vascular damage and delayed cell death in tumors after hyperthermia. Br J. Cancer 41, 309-312.
52. THOMPSON, R.C., PARDOLL, D.M., JAFFEE, E.M., EWEND, M.G., THOMAS, M.C., TYLER, B.M., and BREM, H. (1997). Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J. Immunol. 19, 405-413.
53. TODA, M., MARTUZA, R.L., and RABKIN, S.D. (1998a). In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160, 4457-4464.
54. TODA, M., RABKIN, S.D., and MARTUZA, R.L. (1998b). Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther. 9, 2177-2185.
55. TODA, M., RABKIN, S.D., KOJIMA, H., and MARTUZA, R.L. (1999). Herpes simplex virus as an "in situ vaccine" for the induction of specific antitumor immunity. Hum. Gene Ther. 10, 385-393.
56. TODO, T., RABKIN, S.D., CHAHLAVI, A., and MARTUZA, R.L. (1999). Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum. Gene Ther. 10, 2869-2878.
57. TROJAN, J., JOHNSON, T.R., RUDIN, S.D., ILAN, J., TYKOCINSKI, M.L., and ILAN, J. (1993). Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259, 94-97.
58. WALLACK, M.K., STEPLEWSKI, Z., KOPROWSKI, H., ROSATO, E., GEORGE, J., HULIHAN, B., and JOHNSON, J. (1977). A new approach in specific, active immunotherapy. Cancer 39, 560-564.
59. WHITLEY, R.J. (1996). Herpes simplex viruses. In Fields Virology, 3rd Ed. B.N. Fields, D.M. Knipe, and P.M. Howley, eds. (Lippincott-Raven, Philadelphia) pp. 2297-2342.
60. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GÖNCZÖL, E., and WILSON, J.M. (1994). Cellular immunity to viral antigens limits E1-deleted adertoviruses for gene transfer. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
61. YANG, Y., LI, Q., ERTL, H.C.J., and WILSON, J.M. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
62. YAZAKI, T., MANZ, H.J., RABKIN, S.D., and MARTUZA, R.L. (1995). Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55, 4752-4756.
63. ZAWATZKY, R., HILFENHAUS, J., MARCUCCI, F., and KIRCHNER, H. (1981). Experimental infection of inbred mice with herpes simplex virus type 1. I. Investigation of humoral and cellular immunity and of Interferon induction. J. Gen. Virol. 53, 31-38.
64. ZIEGLER, M.M., NAITO, H., McCARRICK, J.W.I., TOPOLIAN, S.L., RICCI, J.L., and FOX, A. (1986). C1300 murine neuroblastoma: A suitable animal model of human disease. In Malignant Tumors of Childhood. B.F. Brooks, ed. (University of Texas Press, Austin, TX) pp. 114-126.
65. ZIEGLER, M.M., ISHIZU, H., NAGABUCHI, E., TAKADA, N., and ARYA, G. (1997). A comparative review of the immunobiology of murine neuroblastoma and human neuroblastoma. Cancer 79, 1757-1766.